Effect of the new dopaminergic agonist CV 205–502 on plasma prolactin levels and tumour size in bromocriptine-resistant prolactinomas
- 1 January 1991
- journal article
- research article
- Published by Wiley in Clinical Endocrinology
- Vol. 34 (1) , 25-29
- https://doi.org/10.1111/j.1365-2265.1991.tb01731.x
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Bromocriptine as Primary Therapy for Prolactin-Secreting Macroadenomas: Results of a Prospective Multicenter Study*Journal of Clinical Endocrinology & Metabolism, 1985
- Failure of bromocriptine to maintain reduction in size of a macroprolactinoma.BMJ, 1983
- Reenlargement of macroprolactinomas during bromocriptine treatment: report of two casesJournal of Endocrinological Investigation, 1983
- Treatment of hyperprolactinemic states with different drugs: a study with bromocriptine, metergoline, and lisurideFertility and Sterility, 1982
- Size Reduction of Macroprolactinomas by Bromocriptine or Lisuride Treatment*Journal of Clinical Endocrinology & Metabolism, 1981
- Dopaminergic Receptors in Human Prolactin-Secreting Adenomas: A Quantitative Study*Journal of Clinical Endocrinology & Metabolism, 1980
- [3H]Spiperone Binding to Human Anterior Pituitaries and Pituitary Adenomas Secreting Prolactin, Growth Hormone, and Adrenocorticotropic Hormone*Journal of Clinical Endocrinology & Metabolism, 1980
- Effects of bromocriptine on pituitary tumour size.BMJ, 1979
- Treatment of patients with prolactinomasJournal of Endocrinological Investigation, 1978
- Galactorrhoea: Successful Treatment with Reduction of Plasma Prolactin Levels by Brom-ergocryptineBMJ, 1972